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We describe the presentation, management, and clinical outcome of a massive acinic cell carcinoma of the parotid gland. The
primary tumor and blood underwent exome sequencing which revealed deletions in CDKN2A as well as PPP1R13B, which induces
p53. A damaging nonsynonymous mutation was noted in EP300, a histone acetylase which plays a role in cellular proliferation.
This study provides the first insights into the genetic underpinnings of this cancer. Future large-scale efforts will be necessary to
define the mutational landscape of salivary gland malignancies to identify therapeutic targets and biomarkers of treatment failure.
1. Introduction
Salivary gland cancers account for 0.3–0.9% of all cancers
[1, 2], and acinic cell carcinoma (AciCC) accounts for 5–11%
of these [3, 4]. AciCC most commonly arises in the parotid
gland and typically presents at an early stage allowing surgical
treatment with favorable five-year survival rates in excess of
90% [4]. However, approximately 19% of cases present with
advanced stage disease, which is associated with a higher rate
of distant metastases and poorer survival [4]. To date, this
tumor type has not been genetically characterized.
2. Case Report
Our patient is a morbidly obese (375 lbs) 58-year-old woman
who presented to the head and neck surgery clinic with
a right parotid mass and intact facial nerve function. She
underwent a fine needle aspiration which was consistent
with a Warthin’s tumor. CT imaging demonstrated a 5.8 cm
right parotid mass. She was scheduled for surgery, but was
lost to followup. She presented again to the head and neck
surgery clinic one year later with significant interval growth
of the mass and a partial right facial paresis (Figures 1(a)
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Figure 1: Anterior (a) and lateral (b) pictures of the patient at presentation. Axial (c) and coronal (d) CT scan images of the primary tumor.
Note extension of the tumor into the parapharyngeal space with occlusion of the jugular vein (black arrowhead) and skull base involvement
(white arrowhead).
and 1(b)). A CT scan demonstrated a 11.2 × 9.4 × 10.7 cm
mass centered in the right parotid effacing the jugular vein
and abutting the mandible and skull base with extension
along the facial nerve to the geniculate ganglion (Figures
1(c) and 1(d)). She was taken to the operating room and
underwent a radical parotidectomywith facial nerve sacrifice,
radical neck dissection, parapharyngeal space resection, and
lateral temporal bone resection (Figures 2(a), 2(b), and 2(c)).
The tumor was found to be invading the jugular foramen
requiring occlusion of the sigmoid sinus and packing of the
jugular foramen for vascular control. The tumor was also
noted to be extending medially to the geniculate ganglion
of the facial nerve. Gross tumor removal was accomplished
(Figure 2(d)). We were not able to obtain a negative margin
on the proximal facial nerve; thus, the ipsilateral masseter
nerve was grafted to the buccal and marginal mandibular
branches of the distal facial nerve. Her face was further reha-
bilitated with a static palmaris longus sling and temporary
tarsorraphy, which was later replaced with a gold weight. The
defect was reconstructed with a large cervicofacial rotation
flap and a radial forearm free flap (Figure 2(e)). Pathologic
examination revealed a 14 cm low-grade acinic cell carcinoma
with extensive perineural and lymphovascular spread. The
lymph node dissection yielded 29 lymph nodes, all of which
were negative for malignancy. Postoperatively, she received
6000 cGy in 30 fractions using intensity modulated radiation
therapy (IMRT) to the primary site and neck. During and
after radiation, the patient experienced massive weight loss,
losing approximately 200 lbs. Follow-up imaging one year
after treatment revealed no evidence of local or regional
recurrence; however, there was interval development of mul-
tiple newbilateral lung nodules up to 0.9 cmhighly suspicious
for metastases (Figures 3(a) and 3(b)).They were deemed too
small to be biopsied percutaneously.The patient was referred
for consideration of palliative chemotherapy; however, as she
was asymptomatic the decision was made to follow her with
serial imaging.
3. DNA Extraction, Exome Sequencing, and
Bioinformatics Methods
Ethical approval was obtained from the University of West-
ern Ontario Health Sciences Research Ethics and informed
consent was obtained from the patient. DNA extraction
from blood and tumor samples was carried out as previ-
ously described [5]. Exome sequencing was performed by
Otogenetics (Tucker, Georgia) using the Agilent Human All
Exon 50Mbp exome capture kit with 30-fold coverage with
100 base-pair paired-end reads. The reference blood and
primary tumor samples were aligned to the human hg19
reference sequence using Novoalign (v2.07.14). A maximum
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Figure 2: Intraoperative photographs demonstrating the radical parotidectomy with facial nerve sacrifice (a and b). (a) The large arrowhead
indicates the divided jugular vein. (b) The single arrowhead (white) again marks the divided jugular vein, the double arrowhead (white)
indicates residual tumor at the jugular foramen, and the black arrowhead indicates the divided end of the accessory nerve that was grafted
to a cervical rootlet. (c) Temporal bone resection with surgicel occluding the sigmoid sinus (white arrowhead) and a fascia and muscle plug
occluding the eustachian tube (black arrowhead). Demonstration of the primary tumor (d) and reconstruction with a large cervicofacial
advancement flap and radial forearm free flap ((e) arrow marks forearm flap skin paddle).
(a) (b)
Figure 3: Axial CT scan images of the thorax (panels (a) and (b)) demonstrating the interval development of pulmonary metastases
(arrowheads).
of five repeat alignments, defined as having a score difference
of zero, were reported in the final output. SAM formatted
outputwas specifiedwith appropriate read group information
provided. The remaining parameters were set to default
values. Low-quality alignments, defined as alignments with
low confidence in the reported position due to multiple
alignment hits or poor base quality, were removed from the
BAM files using SAMtools (v0.1.18) [6] by specifying the
-q 30 quality filter. Additionally, unaligned and nonprimary
reads (only 1 alignment, called the primary alignment, was
retained in cases of multiple alignments) were removed by
again using SAMtools (v0.1.18) and specifying the -F4 and
–F 256 flags, respectively [6]. PCR artifacts were removed
using MarkDuplicates tool from Picard (v1.66) with default
settings. Samples were then processed as a matched set
through the GATK (v1.3-16) pipeline [7, 8]. Samples were
initially locally realigned using the IndelRealigner walker
from theGATKpackage with known insertions and deletions
found in dbSNP build 135. This was followed by base quality
recalibration using GATK. Finally, variants were called and
filtered using the GATK UnifiedGenotyper and VariantFil-
tration walkers again with default settings. Somatic variants
within the targeted regions were identified using an in-house
Perl library. To be classified as a somatic variant, the following
conditions had to bemet: (1) a tumor variant was identified by
GATK and had a minimum 20x coverage and (2) the variant
base was not seen at that position in the corresponding
normal sample (20x coverage). The genes were annotated
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Figure 4: Somatic whole exome sequencing results across the genome. Vertical lines represent the single-nucleotide variants, while the points
represent copy-number variant calls. Significant CNVs are represented by the green dots with its size reflecting its significance. Segmented
copy-number variants are depicted in red and show clear gains in chromosome 2 and chromosome 9.
Table 1: Somatic non-synonymous single nucleotide variations.
Gene Chr Position Referenceallele
Tumor
allele Zygosity Region Type Transcript Exon
CDS
position
Protein
change
APBA1 9 72067091 C T Hetero Exonic Nonsynonymous NM 001163 9 c.G1915A p.D639N
ARHGAP5 14 32560713 G T Hetero Exonic Nonsynonymous NM 001030055 2 c.G838T p.V280L
CCDC74A 2 132288362 T C Hetero Exonic Nonsynonymous NM 138770 3 c.T506C p.M169T
EP300 22 41523603 A T Hetero Exonic Nonsynonymous NM 001429 4 c.A1019T p.Q340L
GRIK3 1 37324744 G A Hetero Exonic Nonsynonymous NM 000831 7 c.C1069T p.R357C
KIAA0319L 1 35972628 G T Hetero Exonic Stop-gain NM 024874 3 c.C251A p.S84X
KIAA1109 4 123207860 G C Hetero Exonic Nonsynonymous NM 015312 51 c.G9202C p.D3068H
KRT18 12 53343059 C A Hetero Exonic Nonsynonymous NM 199187 2 c.C102A p.S34R
LRRC1 6 53778709 A G Hetero Exonic Nonsynonymous NM 018214 11 c.A1048G p.I350V
LRRC8E 19 7963808 G A Hetero Exonic Nonsynonymous NM 025061 3 c.G401A p.S134N
MYO10 5 16694556 G A Hetero Exonic Nonsynonymous NM 012334 27 c.C3724T p.R1242C
SAMD8 10 76910566 A G Hetero Exonic Nonsynonymous NM 144660 2 c.A280G p.M94V
SLC25A36 3 140675512 C A Hetero Exonic Nonsynonymous NM 018155 2 c.C185A p.P62H
WARS2 1 119575781 T C Hetero Exonic Nonsynonymous NM 015836 6 c.A836G p.H279R
Chr: chromosome, Bolded genes are in cosmic v61.
using RefGene and the consequences of the variations were
identified using ANNOVAR dated 2012-03-08 [9]. As a final
filtration step, any somatic variants, found in genes identified
by Fuentes et al. as possible problematic genes for sequencing
data, were removed [10]. Next, copy-number variants in
the target regions were predicted with contra (v2.0.3) using
default parameters [11]. DNAcopy (v1.32.0) was used to
segment the copy numbers for visualization. This was done
using default settings. Visualizations were generated using
R (v2.15.2) and the lattice (v0.20-11) and latticeExtra (v0.6-
24) packages. Of the target bases, approximately 60% were
covered at a minimum of 20x collapsed coverage in the blood
sample and 63% in the tumor.
4. Interpretation of Identified Mutations
Our bioinformatics pipeline identified 14 nonsynonymous
mutations (Table 1) and significant copy-number variations
(CNVs) in 35 genes including 31 amplifications and 4
deletions (Table 2). CNVs were classified as significant if
they met an adjusted 𝑃 value threshold value of 0.05.
A comprehensive listing of the single-nucleotide vari-
ants, (SNVs) identified including noncoding regions is
provided in the Supplementary Table S1 available online
at http://dx.doi.org/10.1155/2013/270362. The amplifications
occurred preferentially in chromosome 2 (𝑃 = 2.91 ×
10
−21
) and chromosome 9 (𝑃 = 1.59 × 10−18), with single-
amplification loci in chromosomes 14 and 22 (Table 2). The
coding SNVs and all CNVs are illustrated in Figure 4. In addi-
tion, there were two deletions on chromosome 9 (CDKN2A
and MTAP), one on chromosome 14 (PPP1R13B) and one
on chromosome 3 (ETV5). All of the identified single-
nucleotide variant mutations were heterozygous. Thirteen
exhibited nonsynonymous changes in the respective proteins
and one was a nonsense mutation which led to premature
termination of the protein (GRIK3).
Several of these aberrations are plausibly associated to
tumor formation and growth. Most critically, somatic dele-
tion of the potent tumor-suppressor CDKN2Awas identified.
CDKN2A is one of the most widely mutated genes in human
malignancies. According to the ICGC data-coordinating
centre, it is mutated in up to half of glioblastoma multiforme,
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Table 2: Somatic copy-number aberrations.
Gene Chr Start coordinate End coordinate Adjusted mean log ratio 𝑃 value Adjusted 𝑃 value Gain/loss
AAK1 2 69752135 69752264 1.719 1.76𝐸 − 006 1.54𝐸 − 002 Gain
ABCA1 9 107586742 107586862 1.908 1.50𝐸 − 007 2.40𝐸 − 003 Gain
ABCA12 2 215890389 215890509 1.846 7.60𝐸 − 006 3.83𝐸 − 002 Gain
AGAP1 2 236791980 236792100 2.084 6.34𝐸 − 009 1.35𝐸 − 004 Gain
ALDH1A1 9 75533626 75533746 1.595 5.94𝐸 − 006 3.25𝐸 − 002 Gain
ASAP2 2 9508540 9508660 1.931 1.08𝐸 − 006 1.13𝐸 − 002 Gain
CDKN2A 9 21974440 21974830 −4.943 1.48𝐸 − 031 1.42𝐸 − 026 Loss
CERKL 2 182430138 182430258 1.672 1.12𝐸 − 006 1.13𝐸 − 002 Gain
CLASP1 2 122098419 122098539 1.990 2.29𝐸 − 008 4.38𝐸 − 004 Gain
ETV5 3 185823397 185823517 −1.623 4.52𝐸 − 006 2.71𝐸 − 002 Loss
EXD3 9 140250649 140250877 1.883 1.22𝐸 − 005 4.65𝐸 − 002 Gain
GABBR2 9 101156436 101156556 1.864 9.79𝐸 − 008 1.70𝐸 − 003 Gain
GSN 9 124076166 124076316 1.636 8.28𝐸 − 006 3.96𝐸 − 002 Gain
IL18RAP 2 103040817 103040937 1.602 6.85𝐸 − 006 3.64𝐸 − 002 Gain
INPP4A 2 99136444 99136684 1.894 1.99𝐸 − 006 1.65𝐸 − 002 Gain
ITGA4 2 182388877 182388997 1.965 1.44𝐸 − 006 1.38𝐸 − 002 Gain
LOC375190 2 24390449 24390569 2.155 1.82𝐸 − 007 2.68𝐸 − 003 Gain
LOC96610 22 22657565 22657685 1.907 1.01𝐸 − 005 4.29𝐸 − 002 Gain
MERTK 2 112765945 112766169 1.473 7.37𝐸 − 006 3.81𝐸 − 002 Gain
MERTK 2 112778145 112778265 1.707 9.88𝐸 − 006 4.29𝐸 − 002 Gain
MFSD6 2 191354482 191354602 1.980 5.64𝐸 − 007 6.35𝐸 − 003 Gain
MTAP 9 21837897 21838017 −4.841 4.56𝐸 − 045 8.72𝐸 − 040 Loss
NGEF 2 233745847 233745967 1.612 8.93𝐸 − 006 4.17𝐸 − 002 Gain
NUP188 9 131719210 131719330 1.627 2.65𝐸 − 006 2.03𝐸 − 002 Gain
POLR1E 9 37489294 37489414 2.029 2.27𝐸 − 007 3.10𝐸 − 003 Gain
POMT2 14 77753065 77753185 1.796 3.35𝐸 − 006 2.46𝐸 − 002 Gain
PPIG 2 170460673 170460793 1.944 2.96𝐸 − 007 3.77𝐸 − 003 Gain
PPP1R13B 14 104201451 104201571 −1.855 3.88𝐸 − 006 2.48𝐸 − 002 Loss
PSMD5 9 123591371 123591491 1.845 9.39𝐸 − 006 4.28𝐸 − 002 Gain
RNASEH1 2 3596211 3596331 1.911 5.03𝐸 − 006 2.83𝐸 − 002 Gain
SH3RF3 2 109988029 109988149 2.909 2.23𝐸 − 013 7.12𝐸 − 009 Gain
SLC46A2 9 115642010 115642130 1.621 1.14𝐸 − 005 4.45𝐸 − 002 Gain
SULT6B1 2 37415566 37415686 1.530 1.04𝐸 − 005 4.32𝐸 − 002 Gain
TESK1 9 35607906 35608026 1.688 4.54𝐸 − 006 2.71𝐸 − 002 Gain
TTC27 2 32929895 32930015 1.466 1.09𝐸 − 005 4.43𝐸 − 002 Gain
Chr: chromosome, bolded genes are in cosmic v61.
14% of squamous cell carcinomas of the lung, and a third
of all pancreatic adenocarcinomas [12]. It functions by sta-
bilizing TP53 by sequestering the MDM2 ubiquitin ligase
and by inhibiting CDK4-mediated G1 progression through
the cellcycle. In addition, a deletion of 120 nucleotides of
methylthioadenosine phosphorylase (MTAP) was identified,
which is an important protein for salvaging adenine and
methionine [13]. MTAP is located upstream of CDKN2A,
frequently deficient in cancers, and often codeleted with p16
[13].
Also of great note, a nonsynonymous mutation in the
E1A binding protein p300 (EP300) was identified. This
protein functions as a histone acetyltransferase that regulates
transcription via chromatin remodeling and is important in
cell proliferation and differentiation [14]. EP300 interacts
with hundreds of cellular transcriptional regulators [15] and
is a key regulator of p53 function [16].The observedmutation
converts a glutamine to leucine at position 340 within
the TAZ1 (CH1) zinc finger domain, which interacts with
numerous transcription factors [17] and viral oncoproteins
including human papillomavirus E7 [18]. The glutamine that
is mutated is known to be involved in the interaction with
STAT2, a key component of the interferon response, and
potentially many other targets of the TAZ1 domain [19].
EP300 is frequently mutated in several tumour types [20–
22] and its inactivation is thought to play a major role in the
development of small cell lung cancer [21]. Loss of EP300
function would result in unopposed histone deacetylation,
potentially creating an opportunity for targeted therapy with
histone deacetylase (HDAC) inhibitors [23].
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There was also a deletion identified in PPP1R13B which
encodes the apoptosis stimulating of p53 protein 1 (ASPP1)
[24]. Specifically, ASPP1 binds to p53 and enhances its ability
to specifically stimulate expression of proapoptotic target
genes, but not genes involved in cell cycle arrest [25]. Thus,
ASPP1 functions as a tumor suppressor gene and has been
shown to be downregulated in breast cancer [25] and leu-
kemia cell lines [26], suggesting that the loss of this gene
may play an important role in cancer progression. The role
of the mutated genes in initiation and progression of AciCC
identified in our study will require further investigation.
5. Discussion
AciCC is the least aggressivemajor salivary glandmalignancy
[27]. Typically these lesions are present at an early stage with
low-grade histology and are cured at a high rate solely with
surgery [4]. However, a subset presents with higher grade
histology and/or advanced local, regional, and distant disease
that portends a poorer outcome despite the addition of adju-
vant radiation [4]. Currently, there are few treatment options
available to be offered these patients when they relapse. For
rare tumors such as AciCC, the standard mechanism to
identify chemotherapeutic agents through a series of phase I,
II, and III trials is not feasible due to limited patient numbers.
A focused strategy based on tumor biology is necessary. The
advent of massively parallel sequencing has led to incredible
advances in the understanding of tumor genetics and biol-
ogy. Recent exome sequencing of head and neck squamous
cell carcinoma (HNSCC) has revealed that the mutational
landscape of HNSCC is dominated by mutations in tumor
suppressor genes, with only rare targetable mutations in
oncogenes [28, 29]. However, studies of other cancers such
as melanoma have revealed clearly targetable changes such
as activating mutations in BRAF, which have already had a
profound impact on clinical care [30].Our study has provided
the first glimpse of the genetic underpinnings of AciCC,
highlighting changes in the tumor suppressors CDKN2A and
PPP1R13B. There was also a mutation in the histone acetyl-
transferase EP300 that could reduce the acetylation of various
targets.This mutationmaymake this tumormore susceptible
to histone deacetylase inhibitors, which are already showing
promise in vitro and in early-stage clinical trials [31, 32].
Future large-scale studies of salivary malignancies utilizing
next generation sequencing (as for other cancers [33, 34]) will
provide hope for improved patient outcomes.
6. Conclusion
Acinic cell carcinoma is a relatively rare salivary glandmalig-
nancy that typically has a favorable prognosis when treated
solely with surgery. A small subset of these cancers present
with advanced-stage disease which can be associated with
poorer survival despite the addition of adjuvant radiation.
Further study is necessary to understand the biology of
salivary gland malignancies in order to develop adjuvant
therapies to improve outcomes for patients with high-risk
disease.
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